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Abstract
Background: Hypoxia inducible factor-1a (HIF-1a) is responsible for the majority of HIF-1-induced gene expression changes
under hypoxia and for the ‘‘angiogenic switch’’ during tumor progression. HIF-1a is often upregulated in tumors leading to
more aggressive tumor growth and chemoresistance, therefore representing an important target for antitumor
intervention. We previously reported that zinc downregulated HIF-1a levels. Here, we evaluated the molecular mechanisms
of zinc-induced HIF-1a downregulation and whether zinc affected HIF-1a also in vivo.
Methodology/Principal Findings: Here we report that zinc downregulated HIF-1a protein levels in human prostate cancer
and glioblastoma cells under hypoxia, whether induced or constitutive. Investigations into the molecular mechanisms
showed that zinc induced HIF-1a proteasomal degradation that was prevented by treatment with proteasomal inhibitor
MG132. HIF-1a downregulation induced by zinc was ineffective in human RCC4 VHL-null renal carcinoma cell line; likewise,
the HIF-1aP402/P564A mutant was resistant to zinc treatment. Similarly to HIF-1a, zinc downregulated also hypoxia-induced
HIF-2a whereas the HIF-1b subunit remained unchanged. Zinc inhibited HIF-1a recruitment onto VEGF promoter and the
zinc-induced suppression of HIF-1-dependent activation of VEGF correlated with reduction of glioblastoma and prostate
cancer cell invasiveness in vitro. Finally, zinc administration downregulated HIF-1a levels in vivo, by bioluminescence
imaging, and suppressed intratumoral VEGF expression.
Conclusions/Significance: These findings, by demonstrating that zinc induces HIF-1a proteasomal degradation, indicate
that zinc could be useful as an inhibitor of HIF-1a in human tumors to repress important pathways involved in tumor
progression, such as those induced by VEGF, MDR1, and Bcl2 target genes, and hopefully potentiate the anticancer
therapies.
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Introduction
The development of intratumoral hypoxia and angiogenesis is a
hallmark of rapidly growing solid tumors [1]. The presence of
hypoxia renders tumor cells resistant to conventional chemo- and
radiotherapy selecting a more malignant and invasive phenotype
and plays a negative role in patient prognosis [2]. Changes in gene
expression in response to decreased oxygen availability are largely
regulated by hypoxia inducible factor-1 (HIF-1), a heterodimeric
transcription factor which consists of the HIF-1b subunit,
constitutively expressed in cells, and the HIFs-a subunit whose
stability is stimulated by low intracellular oxygen or genetic
alteration [3]. There are two transactivating isoforms, HIF-1a and
HIF-2a, whose expression and activity are tightly regulated by
oxygen and appear to have complementary functions [3,4]. In
normoxia, HIF-1a is hydroxylated by prolyl hydroxylases (PHDs)
at key proline residues (402 and 564) in the oxygen-dependent
degradation domain (ODD) facilitating interaction to von Hippel-
Lindau protein (pVHL), which in turn allows ubiquitination and
subsequent HIF-1a degradation [5,6]. Under hypoxic conditions,
prolyl hydroxylation is inhibited, thereby stabilizing HIF-1a,
which can then translocate into the nucleus and bind to
constitutively expressed HIF-1b, forming the active HIF-1
complex [7]. Transition metals such as cobaltous ions can inhibit
hydroxylation of HIF-1a and therefore induce elevated HIF-1a
levels, mimicking hypoxia [3]. After dimerization with HIF-1b,
HIF-1a binds to a promoter consensus sequence called hypoxia-
responsive element (HRE), and controls the expression of several
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including angiogenesis (e.g., vascular endothelial growth factor -
VEGF), metabolic adaptation (e.g., Glut1), chemoresistance (e.g.,
MDR1), apoptosis resistance (e.g., Bcl2), invasion and metastasis
(e.g., c-Met) [8]. Overexpression of HIF-1a has been found in
many human cancers, including colon, brain, breast, gastric, lung,
skin, ovarian, prostate, renal, and pancreatic carcinoma, and is
associated with poor prognosis and failure of tumor treatment [8].
Likewise, overexpression of HIF-2a has been associated with bad
prognosis in several tumors including prostate cancer [9] and also
to regulate glioblastoma cancer stem cells in the hypoxic niche
[10] that contributes to glioma radioresistance and tumor
repopulation [11]. In tumor cells, HIF-1a can also be regulated
by other genetic factors, such as oncogenes (Ras and phospho-
inositide 3-kinase) or loss of tumor suppressors (VHL or PTEN)
even under aerobic conditions. Inhibition of HIF-1a may,
therefore, represent an attractive strategy with potential for
synergism with other therapies [12,13].
We recently reported a novel way to downregulate HIF-1a
through transcriptional repression by HIPK2, a potential
biomarker for tumor growth [14]. We found that HIPK2 binds
and represses the HIF-1a promoter leading to inhibition of HIF-1
transcription of target genes, including VEGF, MDR1 and Bcl2
[15,16]. Conversely, it has been shown that HIPK2 may be
downregulated under hypoxia [17], interrupting the control
feedback loop between HIPK2 and HIF-1a. Interestingly, we
found that zinc supplementation to cancer cells restores the
hypoxia-induced HIPK2 inhibition, leading to repression of HIF-1
pathway [18]. In this study we further analysed our observations
and evaluated whether zinc could affect HIF-1a at protein level
and which molecular mechanisms were involved. We used an ex
vivo experimental model consisting of cell populations derived from
explants of prostate cancer patients [19] characterized by a
constitutively ‘‘hypoxic’’ phenotype (e.g., stabilized HIF-1a and
HIF-2a protein in normoxia) associated with bad prognosis and a
phenotype negative for HIF-1a and HIF-2a expression under
aerobic condition associated with good prognosis [9], and a
glioblastoma multiforme cell line which is a highly vascular tumor
where expression of VEGF is hypoxia-induced by HIF-1-
dependent transcriptional activation [20] and is relevant for
glioblastoma aggressiveness and invasion [21,22]. We show here
that zinc may interfere with HIF-1a stabilization in human
prostate cancer and glioblastoma cells following hypoxia, either
induced or constitutive, leading to inhibition of HIF1-induced
target genes, and reduction of both tube formation in HUVEC in
vitro and tumor cell invasiveness, by chemoinvasion assay.
Downregulation of HIF-1a in response to zinc was demonstrable
in vivo in a xenograft human glioblastoma model in nude mice
using noninvasive bioluminescent imaging. Therefore, zinc can be
considered an interesting adjuvant in cancer therapy to target
HIF-1a with the potential for disrupting multiple pathways crucial
for tumor growth. This strategy could also improve the efficacy of
established tumor therapies in solid tumors.
Results
Effect of zinc on HIF-1-induced VEGF expression and tube
formation
Our first experiments tested the effect of zinc on HIF-1-
responsive VEGF-luc activity in human U373MG glioblastoma
cells treated with hypoxia (2% O2 or cobalt chloride to mimic
hypoxia). The results of luciferase assay show that the hypoxia-
induced (Figure 1A) as well as the cobalt-induced VEGF-luc
(Figure 1B) activity was strongly inhibited by zinc. Parallel
inhibitory effect was observed with the VEGF mRNA levels
(Figure 1C, D) as well as with the hypoxia- and cobalt-induced
VEGF protein levels (Figure 1A, 1B lower panels) and VEGF
secretion by ELISA assay (Figure 1E). To examine whether the
effect of zinc on VEGF expression was associated with endothelial
cell morphogenesis, the growth of human umbilical vein
endothelial cells (HUVEC) was evaluated in vitro on Matrigel in
the presence of cell-conditioned media (CM) of U373MG cells
untreated or treated with zinc in normoxia and after cobalt
chloride treatment. As shown in Figure 1F, the CM from
U373MG cells provoked a positive effect on the tube formation
of HUVEC which increased further following cobalt treatment.
The tube formation was strongly abolished by zinc supplementa-
tion either in normoxia and hypoxia (Figure 1F). As cobalt
stabilized HIF-1a and to a larger extent also HIF-2a levels and
they were both repressed by zinc (Figure 1G), we evaluated the
requirement of HIF-1a for VEGF inhibition by transducing
U373MG cells with an expression vector encoding the dominant
negative form of HIF-1a without DNA binding and transactiva-
tion domains (HIF-1aDN) [23]. Inhibition of HIF-1a by HIF-
1aDN vector strongly impaired the cobalt-induced VEGF-luc
activity that was not further reduced by zinc (Figure 1H).
Altogether, these data show that zinc inhibited VEGF expression
and tube formation induced by glioblastoma CM and that HIF-1a
was required for zinc-induced VEGF downregulation.
Zinc downregulates HIF-1a and inhibits HIF-1
transcriptional activity
To elucidate the molecular mechanism by which zinc affects the
HIF-1/VEGF signalling, we took advantage of an ex vivo
experimental model consisting of cell populations derived from
explants of prostate cancer patients [19] characterized by a
‘‘constitutively hypoxic’’ phenotype (e.g., stabilized HIF-1a and
HIF-2a protein in normoxia, namely C27) associated with bad
prognosis and a phenotype negative for HIF-1a and HIF-2a
expression under aerobic condition associated with good prognosis
(namely C38) [9]. In C38 cells, HIF-1a is undetectable under
normoxia as previously reported [9] and the hypoxia (2% O2)-
stabilized HIF-1a levels were strongly decreased by zinc
(Figure 2A). In C27 cells, the HIF-1a levels, stabilized in basal
‘‘constitutively hypoxic’’ condition as previously reported [9], were
strongly suppressed following 16 h zinc treatment both in basal
condition and under hypoxia (Figure 2A). Zinc abolished also the
levels of HIF-2a which like HIF-1a dimerizes with HIF-1b and
activates hypoxia-induced transcription, while had no effect on
HIF-1b levels (Figure 2A). Similar results were obtained with
cobalt chloride treatment which inhibits hydroxylation, mimicking
hypoxia (Figure 2B). As a result of HIF-1a downregulation, zinc
abolished the hypoxia-induced HIF-1a recruitment onto its
binding sites in the VEGF promoter in C38 cells and in basal
‘‘constitutively hypoxic’’ condition in C27 cells (Figure 2C);
similarly, zinc inhibited the hypoxia-induced HIF-1a recruitment
onto hTERT promoter (not shown) which has been previously
shown to be regulated by HIFs-a in the prostate cancer model [9].
The zinc-inhibited HIF-1 transcriptional activity was next
analysed by using a transient reporter assay in which endogenous
HIF-1 binds hypoxia response elements (HREs) of VEGF gene
promoter cloned upstream of a luciferase transcriptional reporter
[24]. The hypoxia-driven VEGF-luc activity in both C38 and C27
cells as well as the VEGF-luc activity in C27 cells under basal
‘‘constitutively hypoxic’’ condition were significantly inhibited by
zinc (Figure 2D) which, on the other hand, did not affect the
activity of a VEGF-luc vector mutated in the HIF-1 binding site
(not shown). Consequently, the levels of mRNAs of HIF-1 target
Zinc Induces HIF-1a Proteasomal Degradation
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15048Zinc Induces HIF-1a Proteasomal Degradation
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15048genes such as VEGF, MDR-1 and Bcl2 were significantly
diminished by zinc in both cell lines (Figure 2C, lower panel), in
agreement with our previous results on human colon cancer cells
[18]. These findings indicate that zinc downregulated both HIF-
1a and HIF-2a and impaired HIF-1a recruitment onto target
genes inhibiting HIF-1 transcriptional activity affecting multiple
pathways crucial for tumor growth.
Zinc induces HIF-1a proteasomal degradation
HIF-1a levels are regulated by oxygen-dependent prolyl
hydroxylases enzymes (PHDs) which hydroxylate prolyl residues
402 and 564 in its oxygen-dependent degradation (ODD) domain,
marking HIF-1a for recognition by VHL and targeting it for
proteasomal degradation [5,6]. To determine whether zinc
promotes HIF-1a proteasomal degradation, C38 and C27 cells
were treated with proteasome inhibitor MG132. The zinc-
downregulated HIF-1a levels, under hypoxia in C38 cells and in
basal ‘‘constitutively hypoxic’’ condition in C27 cells, were
completely rescued by treatment with protease inhibitor MG132
(Figure 3A). To further test our hypothesis, we used a plasmid
encoding a fusion protein consisting of the oxygen-dependent
degradation domain of HIF-1a (aa 530–652) fused to the N
terminus of firefly luciferase (ODD-luc). This plasmid behaves like
HIF-1a in living cells and can bind to pVHL oncosuppressor for
HIF-1a degradation, and the intensity of the luciferase signal is
directly proportional to inhibition of the prolyl hydroxylation in the
HIF-1a-ODD domain [25]. As shown in Figure 3B, cobalt
treatment induced the ODD-luciferase activity whereas zinc
significantly decreased it, counteracting the effect of cobalt. Hence,
to evaluate the role of prolyl hydroxylation in the sensitivity of HIF-
1a to zinc, we tested a Flag-tagged HIF-1a expression vector with
prolyl mutations P402A and P564A (HIF-1aP402/P564A) [26]. As
shown in Figure 3C, zinc strongly abolished the hypoxia-induced
(by using either 2% O2 or cobalt) wt-HIF-1a levels as expected; on
the contrary, the HIF-1aP402/P564A mutant appeared to be
resistant to zinc treatment. Then we tested the HIF-1a/VHL
interaction since pVHL only binds to HIF-1a after the latter is
enzymatically hydroxylated on prolyl residues within the ODD
[5,6]. As shown in Figure 3D, the HIF-1a/VHL protein-protein
interaction was reduced by about 80% under hypoxia while it was
strongly reconstituted by zinc. In agreement, endogenous HIF-1a
protein levels were not downregulated by zinc in the RCC4 VHL-
null renal carcinoma cells [27] either in aerobic condition nor
following cobalt treatment (Figure 3E). Similarly, HIF-2a levels
were not downregulated by zinc in the RCC4 cells (Figure 3E).
Finally, the HIF-1-responsive VEGF-luc activity (Figure 3F, upper
panel) as well as the VEGF mRNA levels (Figure 3F, lower panel),
already elevated in RCC4-VHL-null cells under basal condition
and not further induced by cobalt, were not downregulated by zinc.
Altogether, these data support the hypothesis that zinc promoted
HIF-1a proteasomal degradation likely through prolyl hydroxyl-
ation within the ODD and VHL.
Zinc decreases tumor cell invasiveness in vitro and
induces HIF-1a downregulation in vivo
Next, we tested the biological relevance of zinc by Boyden
chamber invasion assay and by in vivo bioluminescence imaging. As
shown in Figure 4A, the ability of U373MG cells to invade was
strongly induced by cobalt and significantly inhibited by zinc.
Interestingly, zinc significantly inhibited U373MG cell invasive-
ness also in basal condition, which correlated with the zinc-
induced inhibition of VEGF mRNA and protein secretion
(Figure 1C, D, E) and with the finding that impairment of VEGF
pathway has been shown to reduce tumor cell invasiveness
[21,22]. Similar inhibition of cell invasiveness was also observed
with the ‘‘constitutively hypoxic’’ C27 prostate cancer cells
(Figure 4B).
Finally, to test whether zinc was able to affect HIF-1a also in
vivo, we took advantage of the bioluminescence imaging technique.
To this aim, human U373MG cells were transfected with the HIF-
1a-ODD-luc or the pcDNA3-luc control vectors and implanted
subdermally into the flanks of athymic nude mice. When the
tumors reached approximately 200 mm
3 (about one week after
injection for both groups), mice were randomized and subse-
quently imaged after intraperitoneal administration of luciferin,
before starting zinc treatment with daily administration. As shown
in Figure 4C, four days of zinc treatment significantly suppressed
HIF-1a-ODD-luc, levels, compared to the HIF-1a-ODD-luc
untreated mice, as measured by bioluminescence (P=0.0033 by
Student t test). Conversely, zinc did not affect control pcDNA3-luc
levels (P=0.3240), indicating specific zinc action on HIF-1a. The
reduction of HIF-1a-ODD-luc after zinc treatment correlated with
strong reduction of intratumoral VEGF mRNA levels (Figure 4D)
as well as with abrogation of VEGF and HIF-1a intratumoral
protein levels (Figure 4E). Collectively, these observations indicate
that zinc was able to inhibit tumor cell invasiveness in vitro. More
importantly, zinc was able to downregulate HIF-1a levels also in
vivo, impairing its transcriptional activity.
Discussion
In this study we analysed the molecular mechanismsby which zinc
downregulated HIF-1a levels and activity in prostate cancer and
Figure 1. Effect of zinc on HIF-1-induced VEGF in glioblastoma and tube formation. (A, upper panel) U373MG glioblastoma cells were
transfected with VEGF-luc reporter and 16 h thereafter treated with 100 mM ZnCl2 and 2% O2 for, respectively 24 and 16 h, before luciferase activity
was assayed. Data are the mean 6S.D. of three independent experiments performed in duplicate. RLU: relative luciferase unit. *, P,0.005. (A, lower
panel) Total cell extracts of cells treated as above were assayed for Western immunoblotting. Anti-tubulin was used as protein loading control.
(B) U373MG glioblastoma cells were transfected with VEGF-luc reporter and 16 h thereafter treated with 100 mM ZnCl2 and 200 mM CoCl2 for,
respectively 24 and 16 h, before luciferase activity was assayed. Data are the mean 6S.D. of three independent experiments performed in duplicate.
RLU: relative luciferase unit. *, P,0.005. (B, lower panel) Total cell extracts of cells treated as in (A) for Western immunoblotting. (C) Total mRNAs
were reverse transcribed from U373MG cells treated as in (A), for semi-quantitative RT-PCR analysis of VEGF expression. Aldolase (ald-A) was used as
internal control. (D) Total mRNAs were reverse transcribed from U373MG cells treated as in (B), for semi-quantitative RT-PCR analysis of VEGF
expression. Aldolase (ald-A) was used as internal control. (E) Serum-starved U373MG cells were cultured for 24 h with 100 mM ZnCl2, and cell
conditioned media were analyzed by ELISA assay for VEGF secretion. ELISA results (mean 6S.D.) for duplicates from four independent experiments
are shown. *, P,0.005 compared with the untreated control. (F) HUVECs were incubated at 37uC on Matrigel with CM form U373MG cells untreated
or treated with ZnCl2 (100 mM) in normoxia or under hypoxia (CoCl2 200 mM for 24 h). The number of tube networks from triplicate wells (10 fields/
well) was quantified at 620 magnification after 3 hours of differentiation. (G) U373MG cells were treated with 100 mM ZnCl2 and 200 mM CoCl2 for,
respectively 24 and 16 h and nuclear cell extracts were assayed for Western immunoblotting. Anti-Hsp70 was used as protein loading control.
(H) U373MG cells were transfected with HIF-1a dominant negative vector (DN-HIF-1a,2mg) and 16 h after transfection treated with 100 mM ZnCl2
and 200 mM CoCl2 for, respectively 24 and 16 h. Luciferase activity was assayed 36 h thereafter and normalized by b-galactosidase activity. Data
represent mean 6S.D. of three independent experiments performed in duplicate. *, P,0.001.
doi:10.1371/journal.pone.0015048.g001
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and its biological relevance. We found that: i) zinc induced HIF-1a
proteasomaldegradation; ii)zincdownregulatedHIF-1ainvitroand in
vivo by using bioluminescence imaging; iii) zinc inhibited HIF-1-
induced VEGF expression and tube formation; iv) zinc-induced
VEGF inhibition correlated with suppression of cell invasiveness.
The observation that zinc induced HIF-1a protein downregu-
lation was corroborated by the use of MG132 proteasome
Figure 2. HIFs-a destabilization and inhibition of HIF-1 transcriptional activity by zinc.( A) Proliferating C38 and C27 prostate cancer cells
were treated with 100 mM ZnCl2 and 2% O2 for, respectively 24 and 16 h. Equal amount of nuclear cell extracts were assayed for Western
immunoblotting. Anti-Hsp70 was used as protein loading control. (B) Proliferating C38 and C27 prostate cancer cells were treated with 100 mM ZnCl2
and 200 mM CoCl2 for, respectively 24 and 16 h. Equal amount of nuclear cell extracts were assayed for Western immunoblotting. Anti-Hsp70 was
used as protein loading control. (C) ChIP analysis with anti-HIF-1a antibody or no antibody as control was performed in C38 cells treated with 100 mM
ZnCl2 and 2% O2 for, respectively 24 and 16 h and in C27 cells treated with100 mM ZnCl2 for 24 h under basal ‘‘hypoxic’’ condition. Recruitment of
HIF-1a onto the VEGF promoter was detected by qRT-PCR, using primers spanning the HRE region. Relative enrichment of HIF-1a compared to no
antibody onto VEGF promoter is shown. The data represent the mean of 2 independent experiments 6S.D. (D, upper panel) C38 and C27 cells were
transfected with VEGF-luc reporter and 16 h after transfection treated with 100 mM ZnCl2 and 200 mM CoCl2 for, respectively 24 and 16 h, before
luciferase activity was assayed. Data represent the mean 6S.D. of three independent experiments performed in duplicate. RLU: relative luciferase unit.
*, P,0.005. (D, lower panel) Total mRNAs were reverse transcribed from C38 and C27 cells treated as above for semi-quantitative RT-PCR analyses of
HIF-1 target genes. Aldolase (ald-A) is shown as internal control.
doi:10.1371/journal.pone.0015048.g002
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15048Figure 3. Zinc induces HIF-1a proteasomal degradation.( A) C38 and C27 cells were treated with 100 mM ZnCl2 for 24 h in the presence or
absence of 10 mM proteasome inhibitor MG132 for 4 h, under hypoxia (200 mM CoCl2 for 16 h) for C38 cells and in basal ‘‘hypoxic’’ condition for C27
cells. Equal amount of nuclear cell extracts were assayed for Western immunoblotting. Anti-Hsp70 was used as a protein loading control. (B) 293 cells
were transfected with HIF-1a-ODD-luc vector and 16 h after transfection treated with 100 mM ZnCl2 and 200 mM CoCl2 for, respectively 24 and 16 h,
before luciferase activity was assayed. Data represent the mean 6S.D. of three independent experiments performed in duplicate. RLU: relative
luciferase unit. *, P,0.005. (C) C38 cells were transfected with either HIF-1a-Flag expression vector or the HIF-1aP402/P564A-Flag mutant and 16 h
after transfection treated with 100 mM ZnCl2 for 24 h and 2% O2 or 200 mM CoCl2 for 16 h. Equal amount of nuclear cell extracts were assayed for
Western immunoblotting with anti-Flag antibody. (D) C38 cells were treated with 100 mM ZnCl2 and 200 mM CoCl2 for, respectively 24 and 16 h, in
the presence of 10 mM proteasome inhibitor MG132 for 4 h. Equal amount of total cell extracts were immunoprecipitated with anti-HIF-1a antibody
and then assayed for Western immunoblotting to detect pVHL interaction. Inputs represent 1/10 of total cell extracts used for immunoprecipitation.
(E) RCC4 VHL-null renal carcinoma cells were treated with 100 mM ZnCl2 and 200 mM CoCl2 for, respectively 24 and 16 h. Equal amount of nuclear cell
extracts were assayed for Western immunoblotting. Anti-Hsp70 was used as protein loading control. (F) RCC4 VHL-null renal carcinoma cells were
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tion (Figure 3A). The effect of zinc on HIF-1a proteasomal
degradation is in agreement with previous observations showing
that a zinc chelator (namely Clioquinol) can stabilize the HIF-1a
protein in normoxia by blocking its ubiquitination, and that
addition of Zinc(II) reverses its effects [28]. Moreover, it has been
shown that antioxidants such as ascorbic acid, N-acetylcysteine
and vitamin C decrease HIF-1a levels by acting on PHD, likely by
maintaining the catalytic ferrous ion of PHD in the reduced active
state, and by inducing VHL-mediated HIF-1a degradation [29].
Although we did not directly measure prolyl hydroxylation in our
model, we showed that zinc was ineffective in downregulating
HIF-1a in the presence of HIF-1a expression vector with prolyl
mutations P402A and P564A (HIF-1aP402/P564A) (Figure 3C)
and in the absence of VHL (in RCC4-VHL null cells) (Figure 3E),
suggesting an involvement of prolyl hydroxylation and VHL.
Of note, we found that zinc inhibited HIF-2a other than HIF-
1a. This is relevant in light of the fact that recent studies in
neuroblastomas have shown that HIF-2a may be the main
regulator of long term hypoxic gene expression and thus confer a
more malignant phenotype [30]. Another study recently estab-
lished the existence of a hypoxic niche that through HIF-2a
regulates glioblastoma cancer stem cells [10] that contribute to
glioma radioresistance and tumor repopulation [11], rendering
this kind or tumor very aggressive and almost incurable.
Moreover, both HIF-1a and HIF-2a cooperate in the activation
of a prognostic transcriptional pattern delineating an aggressive
tumor in the human prostate cancer model that we used in this
study [9], rendering both molecules interesting targets for
anticancer intervention and zinc a valid tool.
The effect of zinc on HIF-1a stability was further evaluate in vivo
by using bioluminescence imaging. We found that a reporter
consisting of the oxygen-dependent degradation domain of HIF-
1a (aa 530–652) fused to the N terminus of firefly luciferase (ODD-
luc) [25] was responsive to zinc treatment in vitro and in vivo. To the
best of our knowledge, this is the first time that has been shown
that intratumoral HIF-1a levels were almost completely abrogated
following 4 days of zinc treatment, by bioluminescence imaging
(Figure 4C). The specificity of zinc action of HIF-1a was
confirmed by Western immunoblotting of tumor tissue extracts
(Figure 4E). In tumor xenografts, decreased HIF-1 activity is
usually associated with a slower growing and less angiogenic tumor
phenotype [31–33], as also assessed by HIF-1a inhibition in a
model of inducible RNA interference in vivo [34]. However, we
have previously shown that zinc treatment alone does not greatly
affect tumor growth per se, at least with the dose and administration
scheduling that we used, rather it changes the activity of
transcription factors (e.g., p53 and HIPK2) important to inhibit
tumor growth and restore/improve chemosensitivity [18,35].
Here, we give a mechanistic explanation of zinc function on
HIF-1a protein regulation and rationalize the use of zinc in
combination with conventional antitumor therapies since zinc
inhibited HIF-1a-induced transcription of target genes important
for chemoresistance such as MDR1 and Bcl2 (Figure 2D).
Finally we showed that zinc could inhibit the HIF-1-induced
VEGF expression which correlated with reduced tumor cell
invasiveness and reduced tube formation (Figure 1 and Figure 4).
This is of interest in light of the fact that multiple angiogenesis
inhibitor have been therapeutically validated in preclinical cancer
models and clinical trials [36]. However, angiogenesis inhibitors
targeting the VEGF pathway have recently demonstrated
antitumor effect in glioblastoma model but concomitantly select
for resistant cells that yield tumor invasiveness and metastasis, due
to activation of HIF-1 pathway [37,38]. Therefore, our results may
be pertinent to translational considerations by targeting both
VEGF and HIF-1 in solid tumors with hypoxic regions or in highly
angiogenic tumors such as glioblastomas. Thus, abrogation of both
HIF-1a and VEGF protein levels was evidenced in tissue tumor
extracts by Western immunioblotting (Figure 4E). Further studies
in orthotopic models for instance of brain tumors are needed to
exploit the potential application of zinc derivatives as adjuvant
with classical antitumoral treatments to prevent the effects of
hypoxia-induced HIF-1 pathway, restore sensitivity to drugs and
suppress tumors.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and in accordance with the Italian and European
legislation. All work was performed in accordance with the
guidelines of the National Cancer Institute ‘‘Regina Elena’’, where
there is currently no active Ethical Committee for animal research,
and has been filed with the Veterinary Service Unit and the Italian
Ministry of Health, in accordance with the Italian and European
legislation.
Cell lines and treatments
Human prostate C38 and C27 cancer cells [9,19], human
embryo kidney 293, RCC4 VHL-null renal cancer cells [27] were
maintained in DMEM (Life Technology-Invitrogen), while human
glioblastoma U373MG cell line (ATCC) was maintained in
RPMI-1640 (Life Technology-Invitrogen), all supplemented with
10% heat-inactivated fetal bovine serum plus glutamine and
antibiotics. Cell treatments were as follow: 100 mM zinc chloride
(ZnCl2), 200 mM hypoxia mimetic cobalt chloride (CoCl2), and
2% O2 for the indicated times. Proteasome inhibitor MG132
(Biomol, Research Laboratories) was added to the culture medium
to a final concentration of 10 mmol/L for 4 h.
Western immunoblotting and co-immunoprecipitation
Total cell extracts and nuclear extracts were prepared
essentially as described [18,39]. For HIF-1a/VHL co-immuno-
precipitation C38 cells were treated with 100 mM ZnCl2 and
200 mM CoCl2 for, respectively 24 and 16 h, in the presence of
10 mM proteasome inhibitor MG132 for 4 h. Total cell extracts
were prepared by incubating at 4uC for 30 min in lysis buffer
(20 mmol/L Hepes, 100 mmol/L NaCl, 5 mM EDTA (pH 8.0),
10% glicerol). Following preclearing for 1 h at 4uC, immunopre-
cipitation was performed by incubating total cell extracts with anti-
HIF-1a antibody pre-adsorbed to protein G-Agarose (Pierce),
rocking for 2 h at 4uC. The beads were then resuspended in 56
Laemmli buffer and subjected to Western blot with the indicated
transfected with VEGF-luc reporter and 16 h after transfection treated with 100 mM ZnCl2 and 200 mM CoCl2 for, respectively 24 and 16 h, before
luciferase activity was assayed. Data represent the mean 6S.D. of three independent experiments performed in duplicate. RLU: relative luciferase unit.
In the lower panel, total mRNAs were reverse transcribed from RCC4 cells for semi-quantitative RT-PCR analysis of VEGF. Aldolase (ald-A) was used as
internal control.
doi:10.1371/journal.pone.0015048.g003
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15048Figure 4. Zinc decreases tumor cell invasiveness in vitro and induces HIF-1a downregulation in vivo. (A) Serum-starved U373MG cells
were treated with 100 mM ZnCl2 and 200 mM CoCl2 for, respectively 24 and 16 h and cell invasion was measured using a Boyden’s chamber invasion
assay. Cell invasion results (mean 6S.D.) for quadruplicates from four independent experiments are shown. *, P,0.0001. (B) Serum-starved C27 cells
were treated with 100 mM for 24 h, under basal ‘‘hypoxic’’ condition and cell invasion was measured as in (A). Cell invasion results (mean 6S.D.) for
quadruplicates from four independent experiments are shown. *, P,0.0001. (C) Representative tumors derived from human U373MG cells
transfected with HIF-1a-ODD-luc and pcDNA3-luc control vectors marked with luciferase were imaged using the IVIS imaging system 200 series at
day 6 after tumor cell injection and at day 10 following 4 days of zinc daily administration. Four mice/group are shown. (D) RNA samples from
explanted tumors, at day 10 after tumor cell injection and after 4 days of zinc treatment, were used for reverse-transcription (RT)-PCR. The mRNA
levels were normalized to GAPDH expression. (E) Tissue samples as in (D) were used for Western immunoblotting of VEGF and HIF-1a levels and anti-
tubulin and anti-Hsp70 were used, respectively, as protein loading control. Similar results were obtained with different tissue samples.
doi:10.1371/journal.pone.0015048.g004
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difluoride (PVDF) membrane (Millipore). Immunoblottings were
performed with the following antibodies: mouse monoclonal anti-
HIF-1a, anti-HIF-2a and anti-HIF-1b, (Novus Biologicals), rabbit
polyclonal anti-VEGF (A-20) (Santa Cruz Biotechnology), rabbit
polyclonal anti-VHL (Cell Signaling), mouse monoclonal anti-
tubulin (Immunological Sciences), and mouse monoclonal anti-
Hsp70 (Stressgene). Immunoreactivity was detected by enhanced
chemiluminescence kit (ECL; Amersham).
Transfection, plasmids and transactivation assay
Luciferase activity was measured in C27, C38 and 293 cells
transiently transfected using respectively the cationic polymer
LipofectaminePlus method (Invitrogen) according to manufactur-
ers’ instructions and the N,N-bis-(2- hydroxyethyl)-2-amino-
ethanesulphonic acid-buffered saline (BBS) version of the calcium
phosphate procedure [40]. The plasmid reporter used were the
VEGF-luc vector that contains the hypoxia response elements
(HREs) of VEGF gene promoter cloned upstream of a luciferase
transcriptional reporter and the VEGF-luc reporter mutated in the
HRE sites [24] (kindly provided by C. Gaetano, IDI, IRCCS,
Rome, Italy), the ODD-luc plasmid that encodes fusion proteins
consisting of HIF-1a (aa 530–652, a unique oxygen-dependent
degradation domain (ODD) fused to the N terminus of firefly
luciferase [25]; the expression vectors encoding the dominant
negative form of HIF-1a without DNA binding domain and
transactivation domain (pCEP4-HIF-1aDN) [23] (kindly provided
by B.H. Jiang, Nanjing Medical University, China), the Flag-
tagged HIF-1a expression vector and the Flag-tagged HIF-1a with
prolyl mutations P402A and P564A [26] (kindly provided by G.L.
Semenza, The Johns Hopkins University School of Medicine,
Baltimore, MD, USA) were also used. The amount of plasmid
DNA in each sample was equalized by supplementing with empty
vector. Transfection efficiency was normalized with the use of a
co-transfected b-galactosidase (b-gal) plasmid. Luciferase activity
was assayed on whole cell extract and the luciferase values were
normalized to b-galactosidase activity and protein content and
expressed as relative luciferase unit (RLU).
RNA extraction and reverse transcription (RT)-PCR
analysis
Cells and tumors were harvested in TRIzol Reagent (Invitro-
gen) and total RNA was isolated following the manufacturer’s
instructions essentially as described [35] by using genes specific
oligonucleotides under conditions of linear amplification. PCR was
performed in duplicate in two different sets of cDNA. PCR
products were run on a 2% agarose gel and visualized by ethidium
bromide staining using UV light. The housekeeping aldolase (ald-
A) mRNA, used as internal control.
Chromatin Immunoprecipitation (ChIP) assays and Real-
time PCR
Chromatin immunoprecipitation assays (ChIP) and real-time
PCR was performed as reported [41]. DNA fragments were
recovered and analyzed by qRT-PCR. Standard curves were
generated by serially diluting the input (5-log dilutions in
triplicate). qRT-PCR was done in the ABI Prism 7500 and
7900HT fast PCR instruments (Applied Biosystems) using SYBR
Master mix (Applied Biosystems) with evaluation of dissociation
curves. The qRT-PCR analyses were performed in duplicate and
the data obtained were normalized to the corresponding DNA
input control. Data are represented as relative enrichment (with
values for no antibody being subtracted from those with antibody).
ELISA and chemoinvasion assay
The VEGF protein levels in the cell-conditioned medium were
determined in triplicate, in 16 h serum-starved U373MG cells, by
enzyme-linked immunosorbent assay (ELISA) using the Quanti-
kine human VEGF immunoassay kit (R&D Systems, Minneapolis,
MN) according to manufacturer’s instructions. VEGF levels were
normalized to cell number and expressed as pg VEGF/10
6 cells/
ml.
Chemoinvasion was assessed using a 48-well modified Boyden
chamber (NeuroProbe, Pleasanton, CA) and 8-mm pore polyvinyl
pyrrolidone-free polycarbonate Nucleopore filters (Costar, New
York, NY), as reported [42]. The filters were coated with an even
layer of 2 mg/ml Matrigel (BD Biosciences). The lower compart-
ment of chamber was filled with chemoattractants (20% FBS) or
with 0.1% BSA as negative control. Serum-starved cells (2610
4
cells) pre-treated with ZnCl2 in the presence or absence of cobalt
were harvested and placed in the upper compartment (40 ml/well)
of the Boyden chamber. After 24 h of incubation at 37uC the
filters were removed and then stained with Diff-Quick (Biomap,
Milan,Italy Merz-Dade, Dudingen, Switzerland), and the migrat-
ed cells in 40 high power fields were counted. Each experimental
point was analyzed in quadruplicate.
Morphogenesis assay on Matrigel
Conditioned media (CM) was prepared by incubating subcon-
fluent U373MG cells in serum-free medium in the presence of
ZnCl2 (100 mM) and CoCl2 (200 mM) for 24 h before harvesting.
Endothelial cell differentiation by using the in vitro Matrigel assay
was performed as previously described [43]. Briefly, a 24-
microwell plate was filled with 100 ml/well of unpolimerized
Matrigel (BD Biosciences, USA) and allowed to polymerize for 1 h
at rool temperature under air flow. Human umbilical vein
endothelial cells (HUVEC) (4610
4 cells/well) were plated into
wells containing CM of U373 cells left untreated or treated with
cobalt and zinc. The number of tubular structures from triplicate
wells (10 fields/well) was quantified at620 magnification after 4 h
of differentiation. Each experiment was performed in triplicate.
In vivo HIF-1a-ODD-luc imaging
CD-1 male nude (nu/nu) mice, 6–8 weeks old and weighting
22–24 g were purchased from Charles River Laboratories (Calco,
Italy). They were housed in specific pathogen-free conditions and
fed standard cow pellets and water ad libitum. Studies were
performed in accordance with institutional standard guidelines for
animal experiments. Human U373MG glioblastoma cells were
transfected with pcDNA3-luc and HIF-1a-ODD-luc vectors and
24 h after transfection, 5610
6 viable cells were injected i.m. on the
flank of each mouse suspended in 0.1 mL PBS. The mice were
examined every day after injection until solid tumors reached
approximately 200 mm
3 weight (6 days from injection). Mice were
then randomized in two groups (4 mice/group) as follow: 1) PBS,
as control; 2) ZnCl2 (10 mg zinc/kg body weight). ZnCl2 was
administrated once daily by oral administration, over the course of
4 days.
Luciferase expression was quantified in vivo in relative units with
a bioluminescence imaging system (IVIS imaging system 200,
Caliper Life Sciences, Hopkiton, MA, USA). This imaging system
was used to measure intratumoral hypoxia in each mouse tumor
according to the degree of reaction between the luciferase enzyme
(the reporter of ODD-luc activity) and a standardized luciferin
substrate stock solution (Caliper Life Sciences). Repeated images of
luciferase expression were acquired according to the manufactur-
er’s specified protocol. Imaging was performed at baseline (day 6
after tumor cell injection) before daily administration of ZnCl2.
Zinc Induces HIF-1a Proteasomal Degradation
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During each imaging session, the mice were anesthetized with a
combination of tiletamine-zolazepam (telazol, Virbac, Carros,
France) and xylazine (Xilazyne/Rompun BAYER) given i.m. at
2 mg/Kg. Then mice were injected i.p. with 150 mg/kg D-
luciferin (Caliper Life Sciences) and imaged in the supine position
and 10–15 min after luciferin injection. Data were acquired and
analyzed using Living Image software version 3.0 (Caliper Life
Sciences).
Statistical analyses
All experiment unless indicated were performed at least three
times. All experimental results were expressed as the arithmetic
mean and standard deviation (S.D.) of measurements was shown.
Student’s t-test was used for statistical significance of the
differences between treatment groups. Statistical analysis was
performed using analysis of variance at 5% (p,0.05) or 1%
(p,0.01).
Acknowledgments
We thank A. Sacchi for her invaluable support and people of the Animal
Facility at the National Cancer Institute Regina Elena for technical
assistance on in vivo experiments.
Author Contributions
Conceived and designed the experiments: GD LN. Performed the
experiments: LN VP RP AA MP AG. Analyzed the data: GD LN AF.
Contributed reagents/materials/analysis tools: CL MS GR AF DG. Wrote
the paper: GD.
References
1. Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in
tumorigenesis. Cell Death Diff 15: 678–685.
2. Brown JM, Wilson WR (2004) Exploiting tumor hypoxia in cancer treatment.
Nat Rev Cancer 4: 437–447.
3. Wang GL, Jiang H, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is
a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc
Natl Acad Sci USA 92: 5510–5514.
4. Tian H, McKnight SL, Russell DW (1997) Endothelial PAS domain protein 1
(EPAS1), a transcription factor selectively expressed in endothelial cells. Genes
Dev 11: 72–82.
5. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFaplha targeted
for VHL-mediated destruction by prolyl hydroxylation: implications for O2
sensing. Science 292: 464–468.
6. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting
of HIF-1alpha to the von Hippel-Lindau ubiquitylation complex by O2-
regulated prolyl hydroxylation. Science 292: 468–472.
7. Kaelin WG, Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of
the HIF hydroxylase pathway. Mol Cell 30: 393–402.
8. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nature Rev Cancer 3:
721–732.
9. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, et al. (2009) Endothelial
NOS, estrogen receptor b, and HIFs cooperate in the activation of a prognostic
transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119:
1093–108.
10. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, et al. (2010) A
hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor
2a. Brain 133: 983–995.
11. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells
promote radioresistance by preferential activation of the DNA damage response.
Nature 444: 756–60.
12. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer
biology and therapeutics. Oncogene 29: 625–634.
13. McCarty MF, Barroso-Aranda J, Contreras F (2010) Practical strategies for
suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypoth 74:
789–797.
14. Nardinocchi L, Puca R, Givol D, D’Orazi G (2010) HIPK2: A therapeutical
target to be (re)activated for tumor suppression. Role in p53 activation and HIF-
1a inhibition. Cell Cycle 9: 1–6.
15. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, et al. (2009)
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2
suggests a novel mechanism to restrain tumor growth. Biochem Biophys Acta
1793: 368–77.
16. Nardinocchi L, Puca R, Sacchi A, D’Orazi G (2009) Inhibition of HIF-1alpha
activity by homeodomain-interacting protein kinase-2 correlates with sensitiza-
tion of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1–10.
17. Calzado MA, de la Vega L, Moller A, Bowtell DD, Schmitz ML (2009) An
inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the
hypoxic response. Nature Cell Biol 11: 85–91.
18. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, et al. (2009) Targeting
hypoxia in cancer cells by restoring homeodomain interacting protein kinase 2
and p53 activity and suppressing HIF-1alpha. PloS ONE 4: 1–12.
19. Nanni S, Priolo C, Grasselli A, D’Eletto M, Merola R, et al. (2006) Epithelial-
restricted gene profile of primary cultures from human prostate tumors: a
molecular approach to predict clinical behavior of prostate cancer. Mol Cancer
Res 4: 79–92.
20. Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible
factor 1. Crit Rev Oncol Hematol 59: 15–26.
21. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth
factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature
359: 845–848.
22. Argyriou A, Giannopoulou E, Kalofonos HP (2009) Angiogenesis and anti-
angiogenic molecularly targeted therapies in malignant gliomas. Oncol Rev 77:
1–11.
23. Zhong X-S, Liu LZ, Skinner HD, Cao Z, Ding M, et al. (2007) Mechanism of
vascular endothelial growth factor expression mediated by cisplatin in human
ovarian cancer cells. Biochem Biophys Res Commun 358: 92–98.
24. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ (1996) Oncogenic
transformation and hypoxia synergistically act to modulate vascular endothelial
growth factor expression. Cancer Res 56: 3436–3440.
25. Safran M, Kim WY, O’Connell F, Flippin L, Gu ¨nzler V, et al. (2006) Mouse
model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of
an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA
103: 105–110.
26. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, et al. (2007) RACK1 competes
with HSP90 for binding to HIF-1alpha and is required for O(2)-independent
and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 25:
207–217.
27. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of
hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene
regulation. Mol Cell Biol 23: 9361–9374.
28. Choi SM, Choi K-O, Park Y-K, Yang EG, Park H (2006) Clioquinol, a Cu(II)/
Zn(II) chelator, inhibit both ubiquitination and asparagines hydroxylation of
hypoxia-inducible factor-1a, leading to expression of vascular endothelial growth
factor and erythropoietin in normoxic cells. J Biol Chem 281: 34056–34063.
29. Gao P, Zhang H, Dinavahi R, Feng L, Xiang Y, et al. (2007) HIF-dependent
antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230–238.
30. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, et al.
(2006) Recruitment of HIF-1alpha and HIF-2alpha to common target genes is
differentially regulated in neuroblastoma: HIF-2alpha promotes and aggressive
phenotype. Cancer Cell 10: 413–423.
31. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM (2000) Suppression of
tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6:
1335–1340.
32. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, et al. (2001) Gene transfer of
antisense hypoxia inducible factor-1 a enhances the therapeutic efficacy of
cancer immunotherapy. Gene Ther 8: 638–645.
33. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG J (2002) Inhibition
of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
Cancer Cell 1: 337–346.
34. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, et al. (2005) Evaluating
hypoxia-inducible factor-1a as a cancer therapeutic target via inducible RNA
interference in vivo. Cancer Res 65: 7249–7258.
35. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, et al. (2008) Reversible
dysfunction of wild-type p53 following homeodomain-interacting protein kinase-
2 knockdown. Cancer Res 68: 3707–3714.
36. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF
treatment with large molecules. Nature Rev 6: 507–518.
37. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christenses JG, et al.
(2009) Accelerated metastasis after short-term treatment with a potent inhibitor
of tumor angiogenesis. Cancer Cell 15: 232–239.
38. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009)
Antiangiogenic therapy elicits malignant progression of tumors to increased local
invasion and distant metastasis. Cancer Cell 15: 220–231.
39. Di Stefano V, Mattiussi M, Sacchi A, D’Orazi G (2005) HIPK2 inhibits both
MDM2 gene and protein by, respectively, p53-dependent and independent
regulations. FEBS Lett 579: 5473–5480.
40. Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells
by plasmid DNA. Mol Cell Biol 7: 2745–2752.
41. Nanni S, Narducci M, Della Pietra L, Moretti F, Grasselli A, et al. (2002)
Signaling through estrogen receptors modulates telomerase activity in human
prostate cancer. J Clin Invest 110: 219–227.
Zinc Induces HIF-1a Proteasomal Degradation
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e1504842. Falk W, Goodwin RH Jr., Leonard EJ (1980) A 48-well micro chemotaxis
assembly for rapid and accurate measurement of leukocyte results. J Immunol
Meth 33: 201–203.
43. Grasselli A, Nanni S, Colussi C, Aiello A, Benvenuti V, et al. (2008) Estrogen
receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates
transcription of human telomerase. Circ Res 103: 34–42.
Zinc Induces HIF-1a Proteasomal Degradation
PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e15048